Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCN-159 in NF2-associated nerve sheath tumors
NCT06553365Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of luvometinib in nerve sheath tumor, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Aug 2024; status: recruiting.
02
Drugs
luvometinib
03
Conditions
nerve sheath tumor
Beyond the preview
Go deeper on NCT06553365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06553365.